Thus far, the different DNA repair inhibitors can be useful in the M phase of cell cycle repair or bypassing the cells with damage because RUNX1 mutations lead to DNA damage and impaired DNA repair [32]. In addition, adriamycin as an antineoplastic drug can stimulate the RUNX1-p53 complex which is important in the activation of p53-mediated apoptosis [11]. L-leucine can be used to improve anemia in the genetic DBA mouse models and DBA patients. This evidence concerns the gene RUNX1 and anemia (phenotype).